There is disclosed a chimeric cetuximab-like monoclonal antibody (CMAB009 mAb) having at least 80% NANA glycosylation terminal sialic acid at an N-glycosylation site Asn297 and a glycosylation pattern of Gal-α(2, 3/6)-Gal. The disclosed CMAB009 monoclonal antibody is a chimeric antibody having the same amino acid sequence (light chain/heavy chain of SEQ ID NO. 1/SEQ ID NO. 3) as cetuximab (Erbitux®) which has at least 80% NGNA terminal sialic acid and a glycosylation pattern of Gal-α(1, 3)-Gal.